On December 30, WuXi Biologics announced a research service cooperation agreement with Sino Biopharmaceuticals to support its discovery of a "First-in-Class" monoclonal antibody with an undisclosed target. According to the agreement, WuXi Biologics will provide integrated research services through antibody discovery technology platforms (such as single B cell technology platforms), generate antibodies based on targets specified by Sino Biopharmaceuticals, and conduct lead antibody discovery, optimization, and developability evaluation, etc., to screen out the best candidate monoclonal antibodies in the preclinical development stage. Sino Biopharmaceuticals will have exclusive rights to the monoclonal antibody and will be responsible for subsequent new drug clinical trial applications (INDs), clinical trials, and product commercialization. WuXi Biologics will receive corresponding payments based on the progress of project development and commercialization.